Printer Friendly

MERCK TO LICENSE TRADEMARK AND MARKETING RIGHTS FOR TWO BRANDS TO THE DU PONT MERCK PHARMACEUTICAL COMPANY AND ITS EUROPEAN SUBSIDIARIES

MERCK TO LICENSE TRADEMARK AND MARKETING RIGHTS FOR TWO BRANDS TO THE DU PONT MERCK PHARMACEUTICAL COMPANY AND ITS EUROPEAN SUBSIDIARIES
 WILMINGTON, Del., June 12 /PRNewswire/ -- Merck (NYSE: MRK) will license trademark and marketing rights to its "Prinivil" (lisinopril) and "Prinzide" (lisinopril-hydrochlorothiazide) brands to The Du Pont Merck Pharmaceutical Company and its subsidiaries in France, Germany, Italy, Spain and the United Kingdom.
 /EDITORS: NO-CHARGE DIAL-UP LOGO ACCOMPANIES THIS STORY/
 (Instructions below)
 In making the announcement today, Merck and Du Pont Merck said that formal transfer of the rights will take place over the next several months in accordance with the various regulatory requirements in each of the five countries.
 The addition of these two cardiovascular medicines to the Du Pont Merck product line will enable the company to expand its cardiovascular marketing expertise. Du Pont Merck has been marketing the cardiovascular medicine "Moduretic" in those five European countries since the company was formed as a partnership of Du Pont and Merck in 1990. Upon their transfer, Merck will no longer market "Prinivil" (lisinopril) and "Prinzide" (lisinopril-hydrochlorothiazide) in those five European countries.
 In a separate agreement, Du Pont Merck will relinquish the rights it previously gained to market its own brand of finasteride for benign prostatic hyperplasia (BPH) in those five countries.
 Upon the completion of these two separate arrangements, Merck will be better able to serve the market for benign prostate enlargement, and Du Pont Merck will be better able to serve the anti-hypertension market.
 Du Pont Merck is a Fortune 500, research-based pharmaceutical company that is jointly owned by Du Pont (NYSE: DD) and Merck & Co., Inc.
 /delval/
 -0- 6/12/92
 /Editors: Du Pont Merck's corporate logo is available without charge on your photo receiver. Have photo editor dial in to 212-967-1293, 212-643-2005 or 212-643-2006 for PRN060192PH1B./
 /CONTACT: Kevin Colgan of Merck & Co., Inc., 908-594-4341 (office) or 908-788-8657 (home) or Roger Morris of The Du Pont Merck Pharmaceutical Company, 302-992-4747 (office) or 215-274-8027 (home)/
 (DD MRK) CO: Du Pont Merck Pharmaceutical Company ST: Delaware IN: MTC SU: LIC


SF -- PH010 -- 9579 06/12/92 09:58 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 12, 1992
Words:349
Previous Article:CURAFLEX HEALTH SERVICES ANNOUNCES CONSOLIDATION OF KANSAS CITY, MO. OPERATIONS
Next Article:ACQUISITION CAPABILITY ANNOUNCES THE FORMATION OF A SUBSIDIARY
Topics:


Related Articles
DU PONT MERCK NAMES HORNER MANAGING DIRECTOR FOR U.K.
DU PONT MERCK EXCEEDS FIRST-YEAR SALES GOAL
DU PONT MERCK, BANYU PLAN JOINT VENTURE FOR JAPAN
DU PONT MERCK NAMES BLANK VP FOR WORLDWIDE MARKETING
DU PONT MERCK HONORS OUTSTANDING SALES ACHIEVEMENTS: DIRECTOR'S CLUB AWARDS
ROBERTS PHARMACEUTICAL CORPORATION ACQUIRES ETHMOZINE, A CURRENTLY MARKETED CARDIOVASCULAR DRUG FROM DU PONT MERCK
THE DU PONT MERCK PHARMACEUTICAL COMPANY AND BRITISH TECHNOLOGY GROUP USA SIGN AGREEMENT TO TRANSFER PHARMACEUTICAL TECHNOLOGIES
Affymetrix Expands GeneChip(R) Supply Agreement With Merck to EasyAccess(TM) Silver Status.
Merck and Bristol-Myers Squibb License New AIDS Drugs to IPM for Development as Microbicides to Protect Women from HIV.
Merck and Bristol-Myers Squibb License New AIDS Drugs to IPM for Development as Microbicides to Protect Women from HIV.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters